Barclays analyst Emily Field initiated coverage of Biogen (BIIB) with an Equal Weight rating and $185 price target The company is improving its pipeline and commercial performance, the analyst tells investors in a research note. Barclays awaits further pipeline news before recommending the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIIB:
- Biogen Announces Board Chair Caroline Dorsa to Step Down
- Biogen chair Caroline Dorsa to retire, Maria Freire to succeed
- Biogen price target raised to $187 from $178 at Wedbush
- Biogen: Leqembi Partnership and Subcutaneous Expansion Drive Multi‑Year Alzheimer’s Growth Opportunity
- Biogen price target raised to $233 from $217 at RBC Capital